TY - JOUR
T1 - Minimally important differences for interpreting European Organisation for Research and Treatment of Cancer (EORTC) Quality of life Questionnaire core 30 scores in patients with ovarian cancer
AU - Musoro, Jammbe Z.
AU - Coens, Corneel
AU - Greimel, Elfriede
AU - King, Madeleine T.
AU - Sprangers, Mirjam A. G.
AU - Nordin, Andy
AU - van Dorst, Eleonora B. L.
AU - Groenvold, Mogens
AU - Cocks, Kim
AU - Velikova, Galina
AU - on behalf of the EORTC Gynecological and Quality of Life Groups
AU - Flechtner, Hans-Henning
AU - Bottomley, Andrew
PY - 2020/11
Y1 - 2020/11
N2 - Introduction: Minimal important differences (MIDs) are useful for interpreting changes or differences in health-related quality of life scores in terms of clinical importance. There are currently no MID guidelines for the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire core 30 (EORTC QLQ-C30) specific to ovarian cancer. This study aims to estimate MIDs for interpreting group-level change of EORTC QLQ-C30 scores in ovarian cancer. Methods: Data were derived from four EORTC published trials. Clinical anchors for each EORTC QLQ-C30 scale were selected using correlation strength and clinical plausibility. MIDs for within-group change and between-group differences in change over time were estimated via mean change method and linear regression respectively. For each EORTC QLQ-C30 scale, MID estimates from multiple anchors were summarized via weighted-correlation. Distribution-based MIDs were also examined as supportive evidence. Results: Anchor-based MIDs were determined for deterioration in 7 of the 14 EORTC QLQ-C30 scales assessed, and in 11 scales for improvement. Anchor-based MIDs for within-group change ranged from 4 to 19 (improvement) and − 9 to −4 (deterioration). Between-group MIDs ranged from 3 to 13 (improvement) and − 11 to −4 (deterioration). Generally, absolute anchor-based MIDs for most scales ranged from 4 to 10 points. Conclusions: Our findings will aid interpretation of EORTC QLQ-C30 scores in ovarian cancer and inform sample size calculations in future ovarian cancer trials with endpoints that are based on EORTC QLQ-C30 scales.
AB - Introduction: Minimal important differences (MIDs) are useful for interpreting changes or differences in health-related quality of life scores in terms of clinical importance. There are currently no MID guidelines for the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire core 30 (EORTC QLQ-C30) specific to ovarian cancer. This study aims to estimate MIDs for interpreting group-level change of EORTC QLQ-C30 scores in ovarian cancer. Methods: Data were derived from four EORTC published trials. Clinical anchors for each EORTC QLQ-C30 scale were selected using correlation strength and clinical plausibility. MIDs for within-group change and between-group differences in change over time were estimated via mean change method and linear regression respectively. For each EORTC QLQ-C30 scale, MID estimates from multiple anchors were summarized via weighted-correlation. Distribution-based MIDs were also examined as supportive evidence. Results: Anchor-based MIDs were determined for deterioration in 7 of the 14 EORTC QLQ-C30 scales assessed, and in 11 scales for improvement. Anchor-based MIDs for within-group change ranged from 4 to 19 (improvement) and − 9 to −4 (deterioration). Between-group MIDs ranged from 3 to 13 (improvement) and − 11 to −4 (deterioration). Generally, absolute anchor-based MIDs for most scales ranged from 4 to 10 points. Conclusions: Our findings will aid interpretation of EORTC QLQ-C30 scores in ovarian cancer and inform sample size calculations in future ovarian cancer trials with endpoints that are based on EORTC QLQ-C30 scales.
KW - EORTC QLQ-C30
KW - Health-related quality of life (HRQOL)
KW - Minimally important difference (MID)
KW - Ovarian cancer
UR - http://www.scopus.com/inward/record.url?scp=85091608164&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.ygyno.2020.09.007
DO - https://doi.org/10.1016/j.ygyno.2020.09.007
M3 - Article
C2 - 32972782
SN - 0090-8258
VL - 159
SP - 515
EP - 521
JO - Gynecologic Oncology
JF - Gynecologic Oncology
IS - 2
ER -